Início › Leucemia Linfocítica Crônica › Flórida
Ensaios clínicos de Leucemia Linfocítica Crônica em Flórida
34 estudos para Leucemia Linfocítica Crônica estão buscando participantes em locais em Flórida.
Cidades em Flórida
- Jacksonville11 estudos
- Miami9 estudos
- Tampa8 estudos
- Sarasota5 estudos
- St. Petersburg4 estudos
- Miami Beach4 estudos
- Cape Coral4 estudos
- West Palm Beach3 estudos
- Kendall3 estudos
Texto oficial do estudo (Inglês)
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
- Holy Cross Hospital, Fort Lauderdale
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 30 de set. de 2026 · NCT04269902A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma
- GC2202 Study Site 103, St. Petersburg
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 30 de set. de 2026 · NCT05645107A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
- Cleveland Clinic Florida, Weston
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 28 de set. de 2026 · NCT06943872A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
- Mayo Clinic Jacksonville, Jacksonville
- Mount Sinai Medical Center Braman Comprehensive Cancer Center, Miami
- Moffitt Cancer Center, Tampa
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 28 de set. de 2026 · NCT07277231A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
- Mayo Clinic Jacksonville, Jacksonville
- Mount Sinai Medical Center Braman Comprehensive Cancer Center, Miami
- Tampa General Hospital Cancer Institute, Tampa
RecrutandoFase 1/2
Idades 18 e acima · Todos os sexos · Atualizado em 28 de set. de 2026 · NCT05006716A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- Mayo Clinic Jacksonville, Jacksonville
- Cancer Specialists of North Florida, Jacksonville
- Mount Sinai Medical Center Braman Comprehensive Cancer Center, Miami
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 28 de set. de 2026 · NCT06973187A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.
- Moffitt Cancer Center, Tampa
RecrutandoFase 1/2
Idades 18 e acima · Todos os sexos · Atualizado em 28 de set. de 2026 · NCT06697184A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors
- Florida Oncology and Hematology, Fort Myers
- Baptist Md Anderson Cancer Center, Jacksonville
- Cleveland Clinic Florida, Weston
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 28 de set. de 2026 · NCT06846671A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).
- Clermont Oncology Center ( Site 5430), Clermont
- Memorial Hospital West ( Site 5410), Pembroke Pines
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 24 de set. de 2026 · NCT05947851A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
- Lynn Cancer Center at Boca Raton Regional Hospital ( Site 0063), Boca Raton
- Clermont Oncology Center ( Site 0046), Clermont
- Florida Cancer Specialists - South ( Site 7001), Fort Myers
- e mais 1
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 24 de set. de 2026 · NCT06136559A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Cancer Specialists, LLC, Jacksonville
RecrutandoFase 4
Idades 18 e acima · Todos os sexos · Atualizado em 22 de set. de 2026 · NCT07218341Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
- SSAK Partners, Coral Springs
- Mayo Clinic - Jacksonville, Jacksonville
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 21 de set. de 2026 · NCT07648264A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
- University of Miami, Coral Gables
- Florida Cancer Specialists, Sarasota
RecrutandoFase 2
Idades 18 e acima · Todos os sexos · Atualizado em 17 de set. de 2026 · NCT07221500Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
- H. Lee Moffitt Cancer Center, Tampa
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 8 de set. de 2026 · NCT03666000Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
- Mayo Clinic, Jacksonville
- Moffitt Cancer Center, Tampa
RecrutandoFase 1/2
Idades 12 e acima · Todos os sexos · Atualizado em 3 de set. de 2026 · NCT04588922Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL
- UM Sylvester Comprehensive Cancer Center at Coral Gables, Coral Gables
- UM Sylvester Comprehensive Cancer Center at Coral Springs, Coral Springs
- UM Sylvester Comprehensive Cancer Center at Deerfield Beach, Deerfield Beach
- e mais 9
RecrutandoFase 3
Idades 65 e acima · Todos os sexos · Atualizado em 2 de set. de 2026 · NCT07321652Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Mount Sinai Comprehensive Cancer Center at Aventura, Aventura
- Schulze Family Foundation Cancer Clinic - Bonita Health Center, Bonita Springs
- Morton Plant Hospital, Clearwater
- e mais 11
RecrutandoEstudo observacionalVoluntários saudáveis bem-vindos
Idades de 40 a 75 · Todos os sexos · Atualizado em 2 de set. de 2026 · NCT05334069Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies
- University of Miami, Coral Gables
RecrutandoFase 1/2
Idades 18 e acima · Todos os sexos · Atualizado em 28 de ago. de 2026 · NCT07520006A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
- Florida Cancer Specialists, Fort Myers
- Cancer Specialists of North Florida -St Augustine, Saint Augustine
- Florida Cancer Specialists East, West Palm Beach
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 17 de ago. de 2026 · NCT05254743Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
- Mayo Clinic, Clinical Trials Referral Office, Jacksonville
RecrutandoFase 1/2
Idades de 13 a 90 · Todos os sexos · Atualizado em 6 de ago. de 2026 · NCT06533579A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
- University of Miami, Miami
- Florida Cancer Specialists, Sarasota
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 2 de jul. de 2026 · NCT05131022A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies
- Mt Sinai Comprehensive Cancer Center, Miami Beach
RecrutandoFase 2
Idades 18 e acima · Todos os sexos · Atualizado em 12 de jun. de 2026 · NCT07271667A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- University of Miami Hospital and Clinics, Sylvester Cancer Center, Miami
RecrutandoFase 2
Idades 18 e acima · Todos os sexos · Atualizado em 19 de mai. de 2026 · NCT06588478A Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Gamunex in Participants With Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma
- Study Site 102, St. Petersburg
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 12 de mai. de 2026 · NCT07582432The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies
- ASCLEPES Research Centers, Weeki Wachee
RecrutandoFase 1/2
Idades de 12 a 95 · Todos os sexos · Atualizado em 15 de abr. de 2026 · NCT04329728A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
- Malcolm Randall V.A. Medical Center /ID# 267825, Gainesville
- Cancer Specialists of North Florida - Jacksonville - AC Skinner Parkway /ID# 266713, Jacksonville
- Mid Florida Hematology And Oncology Center /ID# 269159, Orange City
- e mais 1
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 9 de abr. de 2026 · NCT06428019Predictors of Health-Related QOL in Adults With CLL or Small Lymphocytic Lymphoma
- Moffitt Cancer Center, Tampa
RecrutandoEstudo observacional
Idades 18 e acima · Todos os sexos · Atualizado em 1 de abr. de 2026 · NCT07030400Venetoclax and Obinutuzumab Followed by Epcoritamab for the Treatment of Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma, LonGEVity Trial
- University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami
RecrutandoFase 2
Idades 18 e acima · Todos os sexos · Atualizado em 13 de mar. de 2026 · NCT07218510A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
- Cancer Specialists, LLC, Jacksonville
- Sylvester Comprehensive Cancer Center, Miami
- Florida Cancer Specialists, Sarasota
RecrutandoFase 4
Idades 18 e acima · Todos os sexos · Atualizado em 2 de mar. de 2026 · NCT06876649A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
- Sylvester Comprehensive Cancer Center, Miami
- Florida Cancer Specialists, Sarasota
RecrutandoFase 4
Idades 18 e acima · Todos os sexos · Atualizado em 2 de mar. de 2026 · NCT06876662Study of SGR-1505 in Mature B-Cell Neoplasms
- Napa Research, Pompano Beach
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 13 de fev. de 2026 · NCT05544019B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies
- Mayo Clinic in Florida, Jacksonville
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 13 de fev. de 2026 · NCT06191887AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma
- Mount Sinai Comprehensive Cancer Center, Miami Beach
- Moffitt Cancer Center, Tampa
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 10 de dez. de 2025 · NCT05602363A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies
- Florida Cancer Specialists, Sarasota
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 2 de out. de 2025 · NCT05780034Fonte: ClinicalTrials.gov, dados obtidos em 1 de out. de 2026. Cada estudo define seus próprios critérios de elegibilidade; a equipe do estudo decide quem pode participar.